NLS Pharmaceutics AG

NASDAQ: NLSP · Real-Time Price · USD
2.54
-0.07 (-2.68%)
At close: Aug 15, 2025, 2:38 PM

NLS Pharmaceutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
n/a n/a n/a
Cost of Revenue
11.41K 11.41K 10.05K
Gross Profit
-11.41K -11.41K -10.05K
Operating Income
-11.81M -15.48M -11.86M
Interest Income
n/a 100.87 68.13
Pretax Income
-12.17M -16.5M -11.95M
Net Income
-12.17M -16.5M -11.95M
Selling & General & Admin
5.9M 6.49M 5.93M
Research & Development
5.91M 8.98M 5.92M
Other Expenses
0.00 10.04K -17.32K
Operating Expenses
11.81M 15.47M 11.85M
Interest Expense
145.15K 100.87K 68.13K
Selling & Marketing Expenses
n/a 6.49M 5.93M
Cost & Expenses
11.81M 15.48M 11.86M
Income Tax Expense
n/a 2.00 n/a
Shares Outstanding (Basic)
38.18M 19.68M 14.75M
Shares Outstanding (Diluted)
38.18M 19.68M 14.75M
EPS (Basic)
-0.32 -0.84 -0.81
EPS (Diluted)
-0.32 -0.84 -0.81
EBITDA
-11.8M -15.47M -11.85M
EBIT
-11.81M -15.48M -11.88M
Depreciation & Amortization
11.41K 11.41K 10.05K